US 12263173
PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
granted A61KA61K2039/505A61K2039/545
Quick answer
US patent 12263173 (PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer) held by Cardiff Oncology, Inc. expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Cardiff Oncology, Inc.
- Grant date
- Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K2039/505, A61K2039/545, A61K2300/00, A61K31/437